Brekelmans et al. [8,9] have also reported that breast-cancer-specific survival is not different between BRCA1-mutation carriers and sporadic controls (HR: 1.29, 95% CI: 0.85–1.97). This evidence concerns the gene BRCA1 and breast carcinoma.